IGF-1 DES Guide: Dosage, Reconstitution & Localized Muscle Growth Explained

IGF-1 DES

IGF-1 DES (Des(1-3) IGF-1) is a shortened form of insulin-like growth factor 1 that lacks the first three amino acids of native IGF-1. This change reduces binding to IGF-binding proteins and can increase local biological activity in experimental systems. Most evidence comes from cell and animal research rather than established human clinical use.

How It Works

Reduced IGF-Binding Protein Interaction → IGF-1 Receptor Signaling ↑ → Growth + Metabolic Pathways

Des(1-3)IGF-I is a truncated IGF-1 analog that binds the IGF-1 receptor while interacting much less strongly with IGF-binding proteins. In experimental systems, this can increase the amount of peptide available to act at the receptor. Increased potency has been demonstrated in cell and animal models, but this does not establish site-specific muscle growth or repair in humans.

Important Distinction

IGF-1 DES is a truncated form of IGF-1 with reduced binding to IGF-binding proteins.

It is short-acting relative to longer IGF-1 analogs discussed in research communities.

The idea of site-specific or localized effects comes largely from experimental and community use rather than validated human clinical trials.

Human dosing, pharmacokinetics, and therapeutic use have not been established.

IGF-1 DES Research Protocol

1 mg vial + 1.0 mL BAC Water → 1 unit = 10 mcg → Short-Acting Localized IGF-1 Support

Standard / Targeted Approach

1 mg vial reconstituted with 1.0 mL bacteriostatic water

1 unit = 10 mcg

Per Injection

Lower Discussed Range

Dose20–50 mcg

Units2–5 units

TimingImmediately post-workout most common

Advanced

Higher Discussed Range

Dose50–100 mcg

Units5–10 units

Use ContextAdvanced / targeted research use

Research status:
The 20–100 mcg ranges shown above reflect research/community discussion rather than a clinically validated IGF-1 DES dosing schedule. Human trials have not established a standard dose, titration, injection frequency, or treatment duration.

How to Use IGF-1 DES (Cycle, Timing & Injection)

Research Frequency1–2 injections per day

Research TimingImmediately post-workout most common

RouteIntramuscular localized or subcutaneous

Cycle Length2–4 weeks

Primary UseTargeted local growth / tissue repair signaling

Established Human Frequency, Timing, & Route None established

Best Time to Use

Post-workout timing is commonly discussed, but no controlled human trial has established it as superior.

Because IGF-1 DES is short-acting, timing is usually more important than with longer-acting IGF-1 LR3.

Some advanced protocols discuss 1–2 injections per day, depending on goal and tolerance.

Where to Inject

Localized IM injection is sometimes used with the goal of site-specific activity, but clinical evidence confirming localized muscle growth or repair is lacking.

Subcutaneous use is also discussed, but it is less targeted than localized IM use.

The biological activity of des(1-3)IGF-I should not be interpreted as proof that the injected muscle receives a unique growth advantage.

Rotate injection sites regularly to reduce irritation.

When to Use

During targeted muscle-growth phases

During localized tissue-repair phases

When site-specific anabolic signaling is the research focus

As a short cycle rather than a long continuous protocol

Important distinction:
Localized injection practices come largely from performance-community use and extrapolation from IGF biology. Human clinical studies have not validated site-specific muscle growth from IGF-1 DES injections.

Real-World vs Clinical Use

Real-World Use

Typical Dose20–50 mcg per site

GoalLocalized muscle growth

Clinical / Research Context

FocusTissue repair + growth signaling

RealityShort-acting relative to longer IGF analogs; a validated human half-life for research IGF-1 DES has not been established.

Reconstitution & Dosing

Reconstitution & Dosing

Vial1 mg

Water1.0 mL

Concentration1,000 mcg/mL

Conversion1 unit = 10 mcg

Dose Reference

2 units = 20 mcg

3 units = 30 mcg

5 units = 50 mcg

10 units = 100 mcg

Reconstitution Steps

Draw 1.0 mL bacteriostatic water

Inject slowly into vial or down the vial wall

Gently swirl, do not shake

Allow powder to fully dissolve before use

Refrigerate after reconstitution

Important:
Unit math depends on vial size and water volume. This example uses a 1 mg vial with 1.0 mL added, creating a clean 1 unit = 10 mcg conversion.

Storage & Shelf Life

Storage & Shelf Life

Lyophilized (unmixed)

Refrigerated (2–8°C): ~12–24 months

Frozen (−20°C): up to ~2–3 years

Store sealed, dry, and protected from light

Reconstituted (mixed)

Refrigerated (2–8°C): about 2–3 weeks typical use window

Do not freeze after mixing

Avoid repeated temperature changes

Best Practice

Handling

Keep the vial cold, protected from light, and limit unnecessary handling.

Visual Check

If the solution becomes cloudy, discolored, or contains visible particles, it is safer not to continue using it.

Storage note:
Stability depends on formulation, purity, handling, and storage conditions. General peptide-storage timelines should not be treated as IGF-1 DES-specific stability data.

Research Frame-work Time Between Cycles

Experimental Exposure → Monitor Response → Reassess → Continue or Stop

Research Frame-work Time Between Cycles

Cycle Length2–4 weeks

Time Off2–4 weeks

Long-Term Human Safety Not established

Important distinction:
Common 2–4 week IGF-1 DES cycles and matching off-cycle periods come from research/community practice rather than validated human clinical protocols.

Community Discussion

Option 12–4 weeks on, 2–4 weeks off

Best simple structure for short targeted use

Option 2Use only during a targeted training block

Then stop once the focused growth or repair phase ends

Option 3Short trial phase

Useful for assessing localized response before extending use

When to Stop Sooner

Blood sugar symptoms become noticeable

Dizziness, headache, or discomfort increases

Injection site irritation becomes persistent

You are continuing without a clear targeted goal

Clinical & Preclinical Evidence

Evidence at a Glance

Human Therapeutic Trials Not established

Human Dosing Not established

Human Pharmacokinetics Not established

Evidence Base Primarily cell + animal research

What Research Shows

Des(1-3)IGF-I has much lower affinity for IGF-binding proteins than native IGF-1.

It can show greater biological potency than native IGF-1 in some experimental systems because more peptide remains available to interact with the IGF-1 receptor.

Cell and animal studies have investigated growth, proliferation, differentiation, and anabolic signaling.

These findings do not establish human muscle-growth, repair, or site-specific injection benefits.

Important evidence distinction:

Des(1-3)IGF-I has legitimate experimental biology, but published research does not establish a standardized human therapeutic dose, injection schedule, cycle length, or site-specific muscle-growth protocol.

Monitoring Considerations

Blood glucose and symptoms consistent with hypoglycemia

Dizziness, sweating, shakiness, unusual weakness, or headache

Fluid retention or swelling

Injection-site tolerance

Unexpected growth-related or soft-tissue changes during prolonged exposure

Why glucose matters:
IGF-1 receptor signaling has important metabolic effects, including effects on glucose utilization. Human IGF-1 research provides relevant pathway-level safety context even though it does not establish the safety profile of IGF-1 DES itself.

Research Rationale & Potential Effects

Reduced binding to IGF-binding proteins compared with native IGF-1

Strong IGF-1 receptor activity in experimental systems

Studied in cell and animal models involving growth, proliferation, and tissue-response pathways

Performance-community interest focuses on muscle growth and repair, but these outcomes are not established in controlled human trials

Potential Side Effects

Low blood sugar, also called hypoglycemia

Injection site irritation

Dizziness

Headache

Important Notes

IGF-1 DES is a truncated IGF-1 analog with reduced IGF-binding protein interaction.

Most evidence comes from cell and animal research rather than human therapeutic trials.

A validated human half-life, dose, timing strategy, cycle length, or off-cycle period has not been established.

Localized muscle-growth claims are based largely on theory, preclinical biology, and community practice rather than controlled human evidence.

IGF-1 pathway activity can affect glucose metabolism, making glucose-related effects an important safety consideration.

Important Disclaimer

IGF-1 DES is an investigational research compound and is not FDA-approved for therapeutic use. Human dosing, pharmacokinetics, efficacy, and long-term safety have not been established. This content is for educational purposes only.

Research & References

Primary Research

• Ballard FJ, Francis GL, Ross M, et al. Natural and Synthetic Forms of Insulin-Like Growth Factor-1 (IGF-1) and the Potent Derivative, Destripeptide IGF-1: Biological Activities and Receptor Binding. Biochemical and Biophysical Research Communications. 1987.
• Ballard FJ, Wallace JC, Francis GL, Read LC, Tomas FM. Des(1-3)IGF-I: A Truncated Form of Insulin-Like Growth Factor-I. International Journal of Biochemistry & Cell Biology. 1996.

Research Note: IGF-1 DES (des(1-3)IGF-1) is a truncated IGF-1 analog studied primarily in preclinical and laboratory settings for its reduced binding to IGF-binding proteins and resulting potency. Specific self-administration dosing protocols described on this page are drawn from compounding-community practice and are not directly validated by the cited research.

IGF-1 DES Guide → Browse All Peptides →